Erratum: Lentiviral vectors can be used for full-length dystrophin gene therapy (Scientific Reports (2017) 7 (44775) DOI: 10.1038/srep44775);Lentiviral vectors can be used for full-length dystrophin gene therapy

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Counsell, John R ^a,b,c   Asgarian, Zeinab ^a   Meng, Jinhong ^a   Ferrer, Veronica ^b   Vink, Conrad A ^a   Howe, Steven J ^a   Waddington, Simon N ^c,d   Thrasher, Adrian J ^a   Muntoni, Francesco ^a   Morgan, Jennifer E ^a   Danos, Olivier ^b,e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN;

CELL LINE; DNA TEMPLATE; DUCHENNE MUSCULAR DYSTROPHY; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HUMAN; LENTIVIRUS; METABOLISM; MYOBLAST; PATHOLOGY; PRESCHOOL CHILD; TRANSGENE;

CELL LINE; CHILD, PRESCHOOL; DYSTROPHIN; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LENTIVIRUS; MUSCULAR DYSTROPHY, DUCHENNE; MYOBLASTS; TEMPLATES, GENETIC; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 85015635141     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep46880     Document Type: Erratum

References (53)

1. Hoffman, E. P., Brown, R. H. & Kunkel, L. M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919-28 (1987).
2. Kumar, M., Keller, B., Makalou, N. & Sutton, R. E. Systematic determination of the packaging limit of lentiviral vectors. Hum. Gene Ther. 12, 1893-1905 (2001).
3. Wu, Z., Yang, H. & Colosi, P. Effect of genome size on AAV vector packaging. Mol. Ther. 18, 80-6 (2010).
4. Dong, J. Y., Fan, P. D. & Frizzell, R. A. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum. Gene Ther. 7, 2101-12 (1996).
5. Li, S. et al. A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy. Hum Mol Genet 15, 1610-1622 (2006).
6. Zhang, Y. & Duan, D. Novel mini-dystrophin gene dual adeno-associated virus vectors restore neuronal nitric oxide synthase expression at the sarcolemma. Hum. Gene Ther. 23, 98-103 (2012).
7. Mann, C. J. et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc. Natl. Acad. Sci. USA 98, 42-7 (2001).
8. Lu, Q. L. et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat. Med. 9, 1009-14 (2003).
9. Benchaouir, R. et al. Restoration of human dystrophin following transplantation of exon-skipping-engineered DMD patient stem cells into dystrophic mice. Cell Stem Cell 1, 646-57 (2007).
10. Long, C. et al. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science 345, 1184-1188 (2014).
11. Long, C. et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science, doi: 10.1126/science.aad5725 (2015).
12. Nelson, C. E. et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science science.aad5143, doi: 10.1126/science.aad5143 (2015).
13. Tabebordbar, M. et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351, 407-411 (2015).
14. England, S. B. et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343, 180-2 (1990).
15. Philpott, N. J. et al. Efficient integration of recombinant adeno-associated virus DNA vectors requires a p5-rep sequence in cis. J. Virol. 76, 5411-21 (2002).
16. Dumont, N. A. et al. Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division. Nat. Med. 21, 1455-63 (2015).
17. Yanez-Munoz, R. J. et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat. Med. 12, 348-53 (2006).
18. Al Yacoub, N., Romanowska, M., Haritonova, N. & Foerster, J. Optimized production and concentration of lentiviral vectors containing large inserts. J. Gene Med. 9, 579-584 (2007).
19. Meng, J. et al. Autologous skeletal muscle derived cells expressing a novel functional dystrophin provide a potential therapy for Duchenne Muscular Dystrophy. Sci. Rep. 6, 19750 (2016).
20. Cante-Barrett, K. et al. Lentiviral gene transfer into human and murine hematopoietic stem cells: size matters. BMC Res. Notes 9, 312 (2016).
21. Hu, W. S. & Temin, H. M. Genetic consequences of packaging two RNA genomes in one retroviral particle: pseudodiploidy and high rate of genetic recombination. Proc. Natl. Acad. Sci. USA 87, 1556-60 (1990).
22. Zhang, J. & Temin, H. M. Retrovirus recombination depends on the length of sequence identity and is not error prone. J. Virol. 68, 2409-14 (1994).
23. An, W. & Telesnitsky, A. HIV-1 genetic recombination: Experimental approaches and observations. AIDS Rev. 4, 195-212 (2002).
24. Peliska, J. & Benkovic, S. Mechanism of DNA strand transfer reactions catalyzed by HIV-1 reverse transcriptase. Science (80-). 258, 1112-1118 (1992).
25. Operario, D. J., Balakrishnan, M., Bambara, R. A. & Kim, B. Reduced dNTP Interaction of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Promotes Strand Transfer. J. Biol. Chem. 281, 32113-32121 (2006).
26. Chen, J. et al. High efficiency of HIV-1 genomic RNA packaging and heterozygote formation revealed by single virion analysis. Proc. Natl. Acad. Sci. USA 106, 13535-13540 (2009).
27. Dilley, K. a. et al. Determining the Frequency and Mechanisms of HIV-1 and HIV-2 RNA Copackaging by Single-Virion Analysis. J. Virol. 85, 10499-10508 (2011).
28. Moore, M. D. et al. Dimer initiation signal of human immunodeficiency virus type 1: its role in partner selection during RNA copackaging and its effects on recombination. J. Virol. 81, 4002-11 (2007).
29. Kim, J. H. et al. High Cleavage Efficiency of a 2A Peptide Derived from Porcine Teschovirus-1 in Human Cell Lines, Zebrafish and Mice. PLoS One 6, e18556 (2011).
30. Henderson, D. M., Belanto, J. J., Li, B., Heun-Johnson, H. & Ervasti, J. M. Internal deletion compromises the stability of dystrophin. Hum. Mol. Genet. 20, 2955-63 (2011).
31. Bru, T. et al. Using RT-prone recombination to promote re-building of complete retroviral vectors from two defective precursors: Low efficiency and sequence specificities. J. Virol. Methods 142, 118-126 (2007).
32. Martin, P., Albagli, O., Poggi, M. C., Boulukos, K. E. & Pognonec, P. Development of a new bicistronic retroviral vector with strong IRES activity. BMC Biotechnol. 6, 4 (2006).
33. Skasko, M. & Kim, B. Compensatory role of human immunodeficiency virus central polypurine tract sequence in kinetically disrupted reverse transcription. J. Virol. 82, 7716-7720 (2008).
34. Basu, V. P. et al. Strand transfer events during HIV-1 reverse transcription. Virus Res 134, 19-38 (2008).
35. Arts, E. J., Li, Z. & Wainberg, M. A. Analysis of Primer Extension and the First Template Switch during Human Immunodeficiency Virus Reverse Transcription. J. Biomed. Sci. 2, 314-321 (1995).
36. Suo, Z. & Johnson, K. A. RNA Secondary Structure Switching during DNA Synthesis Catalyzed by HIV-1 Reverse Transcriptase. Biochemistry 36, 14778-14785 (1997).
37. Kanamori, Y. & Nakashima, N. A tertiary structure model of the internal ribosome entry site (IRES) for methionine-independent initiation of translation. RNA 7, 266-274 (2001).
38. Nishiyama, T. et al. Structural elements in the internal ribosome entry site of Plautia stali intestine virus responsible for binding with ribosomes. Nucleic Acids Res. 31, 2434-2442 (2003).
39. Jan, E. & Sarnow, P. Factorless Ribosome Assembly on the Internal Ribosome Entry Site of Cricket Paralysis Virus. J. Mol. Biol. 324, 889-902 (2002).
40. Harrison, G. P., Mayo, M. S., Hunter, E. & Lever, A. M. L. Pausing of reverse transcriptase on retroviral RNA templates is influenced by secondary structures both 5′ and 3′ of the catalytic site. Nucleic Acids Res. 26, 3433-3442 (1998).
41. Klarmann, G. J., Schauber, C. A. & Preston, B. D. Template-directed pausing of DNA synthesis by HIV-1 reverse transcriptase during polymerization of HIV-1 sequences in vitro. J. Biol. Chem. 268, 9793-802 (1993).
42. Abbotts, J., Bebenek, K., Kunkel, T. A. & Wilson, S. H. Mechanism of HIV-1 reverse transcriptase. Termination of processive synthesis on a natural DNA template is influenced by the sequence of the template-primer stem. J. Biol. Chem. 268, 10312-23 (1993).
43. Ellis, B. L., Potts, P. R. & Porteus, M. H. Creating Higher Titer Lentivirus with Caffeine. Hum. Gene Ther. 22, 93-100 (2011).
44. Cribbs, A. P., Kennedy, A., Gregory, B. & Brennan, F. M. Simplified production and concentration of lentiviral vectors to achieve high transduction in primary human T cells. BMC Biotechnol. 13, 98 (2013).
45. Michele, D. E. & Campbell, K. P. Dystrophin-glycoprotein complex: post-translational processing and dystroglycan function. J. Biol. Chem. 278, 15457-60 (2003).
46. Dull, T. et al. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463-8471 (1998).
47. Dogan, R. I., Getoor, L., Wilbur, W. J. & Mount, S. M. SplicePort-an interactive splice-site analysis tool. Nucleic Acids Res. 35, W285-91 (2007).
48. Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L. & Trono, D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15, 871-5 (1997).
49. Zufferey, R. et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72, 9873-9880 (1998).
50. Charrier, S. et al. Quantification of lentiviral vector copy numbers in individual hematopoietic colony-forming cells shows vector dose-dependent effects on the frequency and level of transduction. Gene Ther. 18, 479-87 (2011).
51. De Palma, M. et al. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood 105, 2307-15 (2005).
52. Mock, U. et al. Novel lentiviral vectors with mutated reverse transcriptase for mRNA delivery of TALE nucleases. Sci. Rep. 4, 6409 (2014).
53. Nadai, Y. et al. Protocol for Nearly Full-Length Sequencing of HIV-1 RNA from Plasma. PLoS One 3, e1420 (2008).